HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Register, T. C. Articles by Adams, M. R. Search for Related Content PubMed PubMed Citation Articles by Register, T. C. Articles by Adams, M. R. Related Collections Proteomics and Protein Markers

Serum YKL-40 Is Associated with Osteoarthritis and Atherosclerosis in Nonhuman Primates

¹ Department of Pathology, Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1040;
² College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108

^aauthor for correspondence: fax 336-716-1515)

	Introduction

 
Osteoarthritis (OA) is the leading cause of chronic disability in the US (1). Because individuals with early stages of the disease are often asymptomatic, a biomarker of early OA may be useful. Adult cynomolgus macaques develop naturally occurring OA that closely resembles the human disease (2)(3)(4). Radiographic, histologic, and immunohistochemical analyses show a high frequency of lesions in the knee joints of these animals. Lesions are most severe in the medial tibial plateau and are characterized by fibrillation, clefting, and loss of articular cartilage with a concomitant, marked thickening of the subjacent subchondral bone (4).

YKL-40 (also known as human cartilage glycoprotein-39 or 38-kDa heparin-binding glycoprotein), a major secretory protein of human chondrocytes and synovial cells (5), is increased in the serum and synovial fluid of individuals with joint or cartilage disease (5)(6)(7)(8)(9). YKL-40 mRNA expression is also increased in the cartilage of patients with rheumatoid arthritis (10). YKL-40, first identified as a major product secreted by osteosarcoma MG63 cells (11), is also produced by fibrotic liver cells and breast cancer cells and not by skin or lung fibroblasts [for a review, see Ref. (8)]. YKL-40 expression is induced during the late stages of differentiation in the transition of monocytes to activated macrophages (12)(13), and YKL-40 mRNA is present in macrophages in human atherosclerotic lesions (14).

The N-terminal amino acid sequence of YKL-40 begins with Tyr-Lys-Leu (YKL), and the protein migrates at 40 kDa on sodium dodecyl sulfate polyacrylamide gel electrophoresis; hence the YKL-40 designation. YKL-40 binds heparin (15)(16) and chitin and has structural similarity to chitinolytic enzymes, although it lacks chitinase . . . [Full Text of this Article]

	Acknowledgments

 

	References

 

The following articles in journals at HighWire Press have cited this article:

				J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202. [Abstract] [Full Text] [PDF]

				P. B. Liton, X. Liu, W. D. Stamer, P. Challa, D. L. Epstein, and P. Gonzalez Specific Targeting of Gene Expression to a Subset of Human Trabecular Meshwork Cells Using the Chitinase 3-Like 1 Promoter Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 183 - 190. [Abstract] [Full Text] [PDF]

				J. Dupont, M. K. Tanwar, H. T. Thaler, M. Fleisher, N. Kauff, M. L. Hensley, P. Sabbatini, S. Anderson, C. Aghajanian, E. C. Holland, et al. Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40 J. Clin. Oncol., August 15, 2004; 22(16): 3330 - 3339. [Abstract] [Full Text] [PDF]